

Pimivalimab Biosimilar - Research Grade

Product Code: ICH5266

More Information

Species Reactivity: Human

Target: PD-1

Concentration: >1mg/ml

Isotype: Human IgG4 - kappa

Host: CHO Cells

product name H2: Pimivalimab Biosimilar - Research Grade

Antibodies against the same target: [Anti-Mouse PD-1 \(29F.1A12\) In Vivo Antibody - Low Endotoxin \(ICH1091\)](#), [Anti-PD-1 \(RMP1-14\) \(ICH1132\)](#), [Anti-Mouse PD-1 \(RMP1-14\) Recombinant Antibody \(ICH1182\)](#), [Mouse Anti-Mouse PD-1 \(29F.1A12\) Recombinant Antibody \(ICH1211\)](#), [Anti-Mouse PD-1 \(RMP1-30\) In Vivo Antibody - Low Endotoxin \(ICH1246\)](#), [Anti-Human PD-1 \(J110\) In Vivo Antibody - Low Endotoxin \(ICH1272\)](#), [Nivolumab Biosimilar - Research Grade \(ICH4009\)](#), [Pembrolizumab Biosimilar - Research Grade \(ICH4029\)](#), [Sintilimab Biosimilar - Research Grade \(ICH5001\)](#), [Toripalimab Biosimilar - Research Grade \(ICH5002\)](#), [Camrelizumab Biosimilar - Research Grade \(ICH5003\)](#), [Tislelizumab Biosimilar - Research Grade \(ICH5004\)](#), [Penpulimab Biosimilar - Research Grade \(ICH5112\)](#), [Cemiplimab Biosimilar - Research Grade \(ICH5161\)](#), [Peresolimab Biosimilar - Research Grade \(ICH5221\)](#), [Acrixolimab Biosimilar - Research Grade \(ICH5224\)](#), [Adebrelimab Biosimilar - Research Grade \(ICH5225\)](#), [Enlonstobart Biosimilar - Research Grade \(ICH5234\)](#), [Ezabenlimab Biosimilar - Research Grade \(ICH5238\)](#), [Finotonlimab Biosimilar - Research Grade \(ICH5241\)](#), [Geptanolimab Biosimilar - Research Grade \(ICH5243\)](#), [Iparomlimab Biosimilar - Research Grade \(ICH5248\)](#), [Lipustobart Biosimilar - Research Grade \(ICH5254\)](#), [Nofazinlimab Biosimilar - Research Grade \(ICH5262\)](#), [Pradusinstobart Biosimilar - Research Grade \(ICH5268\)](#), [Pucotenlimab Biosimilar - Research Grade \(ICH5269\)](#), [Sugemalimab Biosimilar - Research Grade \(ICH5278\)](#), [Zimberelimab Biosimilar - Research Grade \(ICH5292\)](#), [Retifanlimab Biosimilar - Research Grade \(ICH5296\)](#), [Dostarlimab Biosimilar - Research Grade \(ICH5311\)](#), [Balstilimab Biosimilar - Research Grade](#)

[\(ICH5369\)](#), [Budigalimab Biosimilar - Research Grade \(ICH5417\)](#), [Cetrelimab Biosimilar - Research Grade \(ICH5434\)](#), [Gilvetmab Biosimilar - Research Grade \(ICH5572\)](#), [Lodapolimab Biosimilar - Research Grade \(ICH5651\)](#), [Pidilizumab Biosimilar - Research Grade \(ICH5773\)](#), [Prolgolimab Biosimilar - Research Grade \(ICH5791\)](#), [Rosnilimab Biosimilar - Research Grade \(ICH5837\)](#), [Rulonilimab Biosimilar - Research Grade \(ICH5840\)](#), [Sasanlimab Biosimilar - Research Grade \(ICH5848\)](#), [Serplulimab Biosimilar - Research Grade \(ICH5855\)](#), [Spartalizumab Biosimilar - Research Grade \(ICH5881\)](#), [Zeluvalimab Biosimilar - Research Grade \(ICH6006\)](#)

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: Q15116

Shipping Conditions: Blue ice

background: This is a research-grade biosimilar of pimivalimab (JTX-4014), an anti-PD-1 antibody. It is an unconjugated, non-therapeutic recombinant analog built around the PD-1 target, produced as a fully human IgG4-kappa immunoglobulin. It is intended strictly for research use only (RUO) and is not the clinical drug; it is not for human or veterinary use. Because it reproduces the antigen-binding behavior of the originator against human PD-1, it is useful as a defined, reproducible reagent for in-vitro and preclinical work: as a positive control or benchmarking standard alongside other checkpoint blockers, in receptor-ligand binding and blockade assays, in reporter and functional T-cell assays, and as a starting antibody for ADCC/ADC or bispecific development workflows. The material is offered at low-endotoxin research grade (typically less than 1 EU/mg, with ultra-low options under 0.5 EU/mg) and available in bulk milligram-to-gram quantities, supporting assay standardization, in-vitro model systems, and larger preclinical studies where lot-to-lot consistency and cost per milligram matter. PD-1 (programmed cell death protein 1; gene PDCD1, UniProt Q15116) is a type I transmembrane co-inhibitory receptor of the CD28/CTLA-4 immunoglobulin superfamily, expressed on activated T cells and also on B cells, NK cells, and some myeloid cells. It engages two ligands, PD-L1 (CD274) and PD-L2 (CD273). Ligand binding clusters PD-1 with the T-cell receptor and recruits the phosphatase SHP-2 via phosphorylated ITIM and ITSM motifs in the cytoplasmic tail, dampening TCR and CD28 signaling. This delivers an inhibitory checkpoint signal that limits T-cell proliferation, cytokine production, and effector function, maintaining peripheral tolerance and restraining immunopathology. Tumors and chronically infected tissues exploit this axis to drive T-cell

exhaustion; blocking PD-1/PD-L1 engagement restores effector responses, the basis of checkpoint-inhibitor immunotherapy.

Other names: Protein PD-1, hPD-1, Programmed cell death protein 1, PDCD1

Specificity: Detects human PD-1

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >95% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.